Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Highlights on the treatment of Early TNBC: The KEYNOTE-522 study

#ESMO23: Breaking Science in Breast Cancer

Login to get immediate access to this content.

Speaker: Peter Schmid, UK

#ESMO23: Breaking Science in Breast Cancer Video Series

Highlights on the treatment of Early TNBC: The KEYNOTE-522 study

Abstract discussed:

LBA18 - Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study

Series objectives: To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews.

Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state of art management and precision oncology in Breast Cancer.

The study results covered, and speakers in this video series, have been selected exclusively by ESMO.

Published on 24 Oct 2023

Back to the Breaking Science in Breast Cancer Video Series